“I struggled to find material about Parkinson’s in Spanish”
Author: Pippa Prendergast-CoatesPublished: 6 August 2020
Prep: Cook: Serves:
How can we “break down the barriers” that surround Parkinson’s? We talk to author, and advocate Dr Maria De León about the need for greater diversity in research and care – and how her experience as a neurologist and person with Parkinson’s has shaped her approach to advocacy
How has your perspective as both a neurologist and person with Parkinson’s defined your approach to campaigning for Parkinson’s?
Although I became a neurologist to work with and help people with Parkinson’s, I never expected it to become a path of self-discovery and a source of so much joy. Living with Parkinson’s, I have learned to channel my energy into empowering others to live full lives despite the condition.
I have spent a lot of time advocating for both patients and caregivers alike by trying to establish better public policies and standards of care, especially among Hispanics and women. Many of my efforts have come from caring for these populations over the years – I’ve witnessed first-hand the lack of resources and inclusivity in national organisations as well as in research.
How can we break down the misconceptions that still surround Parkinson’s?
Although great strides have taken place in the last 30 years, there is still so much we don’t know about Parkinson’s and many myths we need to break down – for example, the idea that only older people or men get Parkinson’s (although data suggests men are at a slightly higher risk).
Breaking down barriers will come about only through an increase in diversity in research. We need active collaboration between national and international health agencies. Since Parkinson’s appears to affect almost all body systems, we also need different fields of neurology and medicine to work together.
This type of collaboration is essential to better understand the ramifications of this complex condition, to be able to make appropriate public policy changes, and to work on personalised medicine for every individual battling a chronic neurodegenerative illness like Parkinson’s.
What motivates you to advocate for the Hispanic Parkinson’s community?
My primary motivation in advocating for Hispanics is the lack of resources available to them. In my practice I struggled to find material in Spanish that spoke beyond information on basic symptoms of Parkinson’s. There were no support groups or studies in which they could participate.
I advocate for Hispanics to become empowered in their own treatment and care, but also try to change the language and manner in which we approach Hispanics and other minorities. If we want to be successful in empowering others to become champions for their health and those of their communities, we must begin using their experiences, cultures and belief systems to get them involved.
Dr Maria De León (far right) advocates for Hispanics to “become empowered in their own treatment”
What can organisations do to improve diversity in clinical research?
One of the things that I have seen is a lack of representation from the Hispanic Parkinson’s community on councils and boards of major organisations – although, organisations like Parkinson’s Foundation have been leading the way in decreasing this disparity by bringing more Hispanics to the table. In January 2020 we had the first ever Hispanic outreach Leadership Conference in Phoenix, Arizona, US.
I think foundations with influence in public policy are slowly becoming aware of the disparities in Parkinson’s care, diagnosis and treatment. They can team up with leaders who are patients or patient advocates in the Hispanic community to increase awareness by helping formulate campaign ads, literature, study protocols in Spanish – and also seek out these leaders to be part of national organisations and patient programmes.
Can you tell us about your work raising awareness of the gender gap in Parkinson’s?
I think we are further along in the fight for gender inclusion and understanding differences in the presentation and progression of Parkinson’s – however we still have a long way to go. We need persistency and perseverance in bringing up these issues at national and international conferences. The future is ripe for changing perceptions about Parkinson’s treatment, diminishing stigmas and knocking down myths.
One of my favourite quotes is by Van Gogh: “There is no blue without yellow and without orange.” By looking into diversity and differences we can better understand the uniqueness of Parkinson’s.
Need to know
Dr Maria De León studied at the University of Pennsylvania, Hahnemann Medical School, and Baylor College of Medicine, US. She is a fellowship trained movement disorder specialist, research advocate and the author of several publications on Parkinson’s. As a woman living with young onset Parkinson’s, she is also a blogger for Health Union and Brain and Life magazine. You can find her personal blogs at defeatparkinsons.com and parkinsonsdiva.org.
For more information about women and Parkinson’s please visit the EPDA website.
Unemployment, debt, poverty & depression… the life of a carer
These 10 statistics highlight the realities of being a carer
4 days ago
Is there a link between Parkinson’s disease and blood vessel dysfunction?
Scientists in Slovakia have investigated the link between blood vessel dysfunction and Parkinson’s – and found that dopamine agonists may have an impact. The team studied the function of the endothelium – a membrane which lines the heart and blood vessels and helps control blood fluidity – in 41 people with the condition and 41 people without. Endothelial function was then measured through a parameter that assessed how easily blood could flow through the vessels. The results showed that while more people with Parkinson’s had endothelial dysfunction compared to those without, the difference did not reach statistical significance. However, the researchers noted that the findings suggested “an association between smoking, dopamine agonists, and impaired endothelial function” in those with the condition. Outlining the study’s limitations, the team noted that more research is needed to explore this potential link.
New swab test may help with Parkinson’s disease diagnosis
Researchers at the University of Manchester, UK, have drawn on one woman’s sense of smell to develop a swab test that may be used to detect Parkinson’s. The scientists used the test to analyse sebum (a type of oily substance on the skin) in 79 people with Parkinson’s and a control group of 71 healthy individuals. The team identified more than 4,000 different compounds in the participant samples – including 500 that were unique to those living with the condition. The test was developed with the help of Joy Milne from Perth, Scotland, whose unique sense of smell meant that she noticed a change in her late husband Les’s odour twelve years before he was diagnosed with Parkinson’s. Speaking to the BBC, Professor Perdita Barran, who led the research, described the test as potentially “transformative” – and said that the team hopes to roll the test out to people in…
Could a national biobank help inform the future of Parkinson’s disease treatment in Australia?
A biobank is a collection of biological samples and data designed to be used for research. Now, researchers in Australia are working to build a biobank for Parkinson’s. As part of the project, the scientists are conducting scans of people that have been injected with fluorodopa – a substance that highlights dopamine in the brain. Participants include people living with Parkinson’s and a control group of people without the condition. The resulting database of scans will be used to create a national biobank that aims to inform treatment and research into the condition. Commenting on the study, Olivia Nasser – executive director at the Hospital Research Foundation, which is helping to fund the research – said, “Once we build up the biobank of scans, it can actually be used as an effective way to treat Parkinson’s.” The researchers encourage people with and without Parkinson’s to take part in the trial.